Cellectar Biosciences, Inc. (CLRB)
NASDAQ (CM) NASDAQ (CM) Primary 
XFRA 
Cellectar Biosciences, Inc. (CLRB) Q2 2024 Earnings Call Transcript
Cellectar Biosciences, Inc. (NASDAQ:CLRB ) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Jim Caruso – President and Chief Executive Officer Andrei Shustov – Senior Vice President-Medical Jarrod Longcor – Chief Operating Officer Shane Lea – Chief Commercial Officer Chad Kolean – Chief Financial Officer Conference Call Participants Jonathan Aschoff – ROTH Jeff Jones – Oppenheimer Ted Tenthoff – Piper Sandler Operator Good morning, and welcome to Cellectar Biosciences Second Quarter 2024 Financial Results Call. Today's call is being recorded.
Cellectar: WM Treatment Data Leads To A Few Regulatory Milestones
Cellectar Biosciences, Inc. announced that the primary endpoint was met in the pivotal phase 2 CLOVER WaM study, using iopofosine for the treatment of patients with relapsed/refractory Waldenstrom's Macroglobulinemia or WM. The NDA submission of ipofosine for relapsed/refractory WM patients is expected in Q4 of 2024. The potential to have therapy given Priority Review. The company believes that the possible market for relapsed/refractory WM patients in the United States stands at a $1.05 billion market opportunity.
Cellectar Biosciences: Still Working On That Hit (Maintain Buy)
Cellectar Biosciences, Inc. is focused on developing a radiopharmaceutical for Waldenstrom's macroglobulinemia, a type of non-Hodgkin lymphoma. The company has positive topline data from a pivotal study, with a high response rate in patients with Waldenstrom's macroglobulinemia. Cellectar Biosciences has a strong pipeline and potential for commercialization, but cash concerns and the timeline for approval are risks.
